Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Nalka Strukturfond AB in connection with the acquisition of Cibes
Mandate

Vinge advised Nalka Strukturfond AB in connection with the acquisition of Cibes

June 13, 2017 Banking and Finance

Vinge has advised Nalka Strukturfond AB in connection with the acquisition of CL Intressenter AB (”Cibes”) from R12 Kapital Fund I AB as well as a number of minority owners.

Cibes is a leading manufacturer of platform lifts with its base in Gävle and with global operations. The transaction is conditional upon approval by the relevant competition authorities.

Vinge’s team consisted of responsible partner Jonas Johansson and partner Peter Sundgren together with, among others, associates Johan Mattsson, Peter Issa, Andrea Ahlgren, Lova Unge, Jasmin Draszka Ali, Frida Ställborn, Ilze Lukins, Lionardo Ojeda, Fredrika Hjelmberg, Martin Boström, Grant McKelvey and Xandra Ståhlberg as well as senior counsel Qun Gu and VDR specialist Anna Hellohf. Partner Louise Brorsson Salomon together with associate Helena Håkansson provided acquisition financing advice.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024